Navigation Links
The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial
Date:12/3/2008

WHITE PLAINS, N.Y., Dec. 3 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Memgen, LLC jointly announce the beginning of a new clinical trial of ISF35, a cancer vaccine, at the University of California, San Diego (UCSD).

LLS is collaborating on this trial in the hopes that it will speed the development and approval of a novel approach aimed at treating patients with fludarabine refractory and/or 17p deleted chronic lymphocytic leukemia (CLL).

Doctors at UCSD have already begun treating the first patient with ISF35. They plan to enroll up to twelve patients. These patients will receive a vaccine expressing an immune-boosting molecule, ISF35 (Immune Stimulatory Factor 35), followed by three courses of rituximab plus the chemotherapy drugs fludarabine and cyclophosphamide (FCR).

"This clinical study builds upon three previous trials already completed at M.D. Anderson and here at UCSD," said Januario E. Castro, M.D., assistant clinical professor at the UCSD School of Medicine and the Moores Cancer Center, who leads the work. "Those trials showed remarkable results for ISF35 in patients with high risk and treatment-resistant CLL. Most importantly, ISF35 was well-tolerated with only minimal side effects, reduced CLL cells and lymph nodes in nearly every patient, and when combined with chemotherapy produced complete or partial remissions in patients with 17p deleted CLL."

"There is a clear unmet medical need for new therapies to treat refractory or relapsed CLL, and in particular 17p- patients," said Louis J. DeGennaro, Ph.D., LLS's chief scientific officer. "Our goal is to bring new treatment options to these patients quickly."

For more information about participating in this clinical trial, contact Denise Darrah, at the Moores UCSD Cancer Center, 858-822-5375, or ddarrah@ucsd.edu or the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

About Memgen, LLC

Memgen is a clinical stage biotechnology company with offices in Dallas and San Diego. Memgen was founded four years ago to develop non-toxic and targeted active immunotherapies for the treatment of cancers. Its lead product, ISF35, has demonstrated potent anti-leukemic activity as a single agent and is well-tolerated. ISF35 generates none of the immunosuppressive activities associated with standard cancer treatments.

For more information about Memgen, visit www.memgenbio.com.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

    LLS Contact: Andrea Greif
    914.821.8958
    andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse
3. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
4. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
7. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
8. Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
9. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 ... "Pain Management in the U.S.: Consumer Strategies" report to ... ... on how adults approach and treat their physical pain, emphasizing ... two distinct groups: pain sufferers and adults who have selected ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... YORK , March 24, 2017 ... ... a leading publisher of cannabis market research, the legal cannabis ... percent CAGR through 2021, despite conflicting signals from the current ... points out that the two biggest drivers of growth in ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business ... Awards . The annual awards, now in their 12th year, are among the most ... winners. , In 2016, the awards were retooled to recognize achievements in both large ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... they are now offering treatments for sleep apnea and TMJ at their office. ... Sleep apnea , specifically the obstructive type, is increasingly being treated at dental ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health (“GH”) ( ... patients for colonoscopy at the HyGIeaCare® Center that is to be located adjacent ... , The HyGIeaCare® Prep, cleared by the U.S. Food and Drug Administration ...
(Date:3/24/2017)... ... ... Time GPS”: a dauntless and enlightened study of the second-coming of Christ, and ... published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation as ... ninety-one, he shares the Wisdom God bestowed upon him in this publication. , ...
Breaking Medicine News(10 mins):